David Allmond
Corporate Officer/Principal chez POOLBEG PHARMA PLC
Fortune : 24 289 $ au 31/03/2024
Profil
David Allmond is currently the Chief Business Officer at Poolbeg Pharma Plc since 2023.
Prior to this, he was the Chief Executive Officer & Director at Novacyt SAS from 2021 to 2022.
He also held positions as Vice President-Global Marketing at Celgene Corp.
from 2006 to 2012, President-Europe, Middle East & Africa Regions at Aegerion Pharmaceuticals, Inc., and Chief Commercial Officer at Amryt Pharma Holdings Ltd.
from 2017 to 2020.
Additionally, he served as a Director at Myeloma UK.
Mr. Allmond received his undergraduate degree from Imperial College London.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NOVACYT SAS
0,06% | 31/12/2022 | 43 500 ( 0,06% ) | 24 289 $ | 31/03/2024 |
Postes actifs de David Allmond
| Sociétés | Poste | Début |
|---|---|---|
| POOLBEG PHARMA PLC | Corporate Officer/Principal | 01/12/2023 |
Anciens postes connus de David Allmond
| Sociétés | Poste | Fin |
|---|---|---|
| NOVACYT | Chief Executive Officer | 09/11/2022 |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01/09/2020 |
| CELGENE | Sales & Marketing | 01/01/2012 |
Myeloma UK
 Myeloma UK Medical/Nursing ServicesHealth Services Myeloma UK is a charity organization that focuses on providing information and support to individuals affected by the incurable blood cancer, myeloma. If you are worried about your myeloma relapsing, Myeloma provides all the necessary information and support. The non-profit company is based in Edinburgh, UK, and was founded in 1998. The British company ensures that patients have access to the best treatments and have been transforming lives since their establishment in 1997. The organization's main goal is to give a voice to myeloma patients and their related conditions. The CEO is Rosemarie Finley. | Director/Board Member | - |
| AEGERION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de David Allmond
| Imperial College London | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NOVACYT | Health Technology |
| POOLBEG PHARMA PLC | Health Technology |
| Entreprise privées | 4 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Myeloma UK
Myeloma UK Medical/Nursing ServicesHealth Services Myeloma UK is a charity organization that focuses on providing information and support to individuals affected by the incurable blood cancer, myeloma. If you are worried about your myeloma relapsing, Myeloma provides all the necessary information and support. The non-profit company is based in Edinburgh, UK, and was founded in 1998. The British company ensures that patients have access to the best treatments and have been transforming lives since their establishment in 1997. The organization's main goal is to give a voice to myeloma patients and their related conditions. The CEO is Rosemarie Finley. | Health Services |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
